Abstract: The disclosure provides polypeptides that bind tripeptide repeat sequences and having an amino acid sequence at least 50%, identical to the amino acid sequence of any one of SEQ ID NO: 1-105, nucleic acids encoding such polypeptides, expression vectors including such nucleic acids, and host cells including such polypeptides, nucleic acids, and/or expression vectors.

Abstract: Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.

Abstract: The technology as described herein relates to discovery of methods for generating odontoblasts or organoids thereof in vitro and compositions that utilize the generated odontoblasts for restoring tooth structure.

Abstract: Centrifugal clutch mechanisms, and transmissions and lawnmowers having centrifugal clutch mechanisms are provided. A centrifugal clutch mechanism includes a clutch bell comprising an annular wall and a circular ring extending away from the annular wall to define an internal cavity, wherein the circular ring comprises an inward facing surface defining a drive surface. The centrifugal clutch mechanism also includes a plurality of centrifugal weights disposed in the internal cavity and an inward biasing element engaged with the centrifugal weights. The inward biasing element biases the centrifugal weights towards a disengaged position in which the centrifugal weights do not interface with drive surface, and upon application of a sufficient centrifugal force, the centrifugal weights are configured to transition to an engaged position in which the centrifugal weights interface with the drive surface.

Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.

Abstract: A system for deploying an implant cut from a biological tissue into an eye of a patient including a delivery device and a nose cone assembly, a tubular shaft projecting from the distal end region of the nose cone and comprising a lumen. Related devices, systems, and methods are provided.

Abstract: Provided are molecular feedback circuits employing caged-degrons. Aspects of such circuits include the use of a caged-degron to modulate the output of a signaling pathway in a feedback-controlled manner. Also provided are nucleic acids encoding molecular circuits and cells containing such nucleic acids. Methods of using caged-degron-based molecular feedback circuits are also provided, including e.g., methods of modulating a signaling pathway of a cell that include genetically modifying the cell with a caged-degron-based molecular feedback circuit.

Abstract: The invention provides compositions and methods for treating celiac sprue.

Abstract: The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.

Abstract: The present invention relates to methods and compositions for the high throughput screening of protein-protein interactions in yeast liquid culture. Protein fusions non-native to yeast may be expressed to replace endogenous sexual agglutination proteins and mediate library-by-library interrogation of protein interactions. The methods and compositions of the invention can be utilized for the characterization of protein interaction networks in high throughput for both binding affinity and specificity, which is crucial for understanding cellular functions, screening therapeutic candidates, and evaluating engineered protein networks.

Abstract: A system for deploying an implant cut from a biological tissue into an eye of a patient including a delivery device and a nose cone assembly, a tubular shaft projecting from the distal end region of the nose cone and comprising a lumen. Related devices, systems, and methods are provided.

Abstract: Polypeptides are provide having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-17, wherein the polypeptide binds to a chlorophyll (Chl) dimer, and scaffolds thereof.

Abstract: Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety.

Abstract: The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.

Abstract: The present disclosure is generally directed to macrocyclic oligoamides useful in the inhibition of HDAC6, and methods for treating diseases that are ameliorated by the inhibition of HDAC6.

Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

Abstract: Polypeptides having an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1-20 and 33-58 are provided, fusion proteins thereof, kits thereof, and methods for their use as sensing devices and for other uses.

Abstract: Polypeptides having an amino acid sequence at least 50% identical to, and identical at least at one identified interface position, to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-44, and polypeptides having an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 45-58, are provided, as well as fusion proteins thereof, nanoparticles thereof, and methods for treating or limiting development of an infection.

Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.

Abstract: Conditionally active receptor agonists that, when activated, bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?cheterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are components of the conditionally active receptor agonists and methods for using the conditionally active receptor agonists.